Brief: Monopar Announces Camsirubicin Clinical Program Update - Improved Side Effect Profile Seen To Date Compared To Doxorubicin
14/02/2023 12:52
Feb 14 (Reuters) - Monopar Therapeutics Inc MNPR.O :
* MONOPAR ANNOUNCES CAMSIRUBICIN CLINICAL PROGRAM UPDATE -
IMPROVED SIDE EFFECT PROFILE SEEN TO DATE COMPARED TO
DOXORUBICIN
* MONOPAR THERAPEUTICS INC - HAS OPENED ENROLLMENT FOR FIFTH
DOSE
LEVEL COHORT, AT AN INCREASED DOSE OF 650 MG/M
Source text for Eikon: ID:nGNX4W1wqf
Further company coverage: MNPR.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Monopar Therapeutics
See all newsBrief: Monopar Appoints Jeffrey D. Kent, M.D., As Executive Vice President, Head Of Medical Affairs Announces Two Alxn1840 Presentations At Aasld – The Liver Meeting 2026
U.S. RESEARCH ROUNDUP-Airbnb, Five Below, Silgan Holdings
Monopar Therapeutics Inc. reports results for the quarter ended June 30 - Earnings Summary
Monopar Therapeutics Inc. expected to post a loss of 62 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Alphabet, IBM, Tesla